A case of long-term therapy of hepatocellular carcinoma with atezolizumab and bevacizumab combination

Hepatocellular carcinoma is the most common primary malignant neoplasm of the liver, accounting for more than 90% of cases. Before the introduction of targeted therapy, there were virtually no options for the treatment of unresectable HCC. Currently, sorafenib and lenvatinib are registered as first-line therapy for unresectable HCC. The introduction of the combination of atezolizumab and bevacizumab has significantly improved the results of HCC treatment. In the IMbrave 150 study, the median OS was 19.2 months in the atezolizumab and bevacizumab group and 13.4 months in the sorafenib group. The median progression-free survival was 6.9 and 4.3, respectively. The presented clinical observation describes a case of treatment of a patient with unresectable HCC, a large tumor burden and portal vein thrombosis. In the first line of therapy, we considered the combination of atezolizumab and bevacizumab. A rapid response to the therapy was obtained, a complete response was registered after 42 months of therapy with a combination of atezolizumab and bevacizumab. A minimum number of adverse events and satisfactory tolerability were noted. Currently, the patient continues therapy with this combination. Currently, an increasing number of patients receive therapy with atezolizumab and bevacizumab for a long time. Experience is accumulating in real clinical practice of monitoring patients who have been receiving a combination of immunooncologic and targeted drugs for a long time.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

2. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global viewof hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. https://doi.org/10.1038/s41575-019-0186-y.

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et. all. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.

4. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. https://doi.org/10.1016/S0140-6736(22)01200-4.

5. Serebrennikov GA, Menshikov KV, Sultanbaev AV, Musin ShI, Menshikova IA, Sultanbaeva NI et al. Atezolizumab and bevacizumab in therapy for patients with hepatocellular carcinoma in real clinical practice. Creative Surgery and Oncology. 2023;13(2):131–142. (In Russ.) https://doi.org/10.24060/2076-3093-2023-2-131-142.

6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S14702045(08)70285-7.

7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. https://doi.org/10.1056/NEJMoa0708857.

8. Menshikov KV, Sultanbaev AV, Musin ShI, Menshikova IA, Abdeev RR, Sultanbaeva NI et al. Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. Meditsinskiy Sovet. 2022;16(9):31–39. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-9-31-39.

9. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet. 2018;391(10126): 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.

10. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664–671. https://doi.org/10.1002/ijc.23131.

11. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. https://doi.org/10.1002/hep.29086.

12. Menshikov KV, Sultanbaev AV, Akhmetgareeva KT, Lipatov DO. Treatment of metastatic hepatocellular carcinoma with len-vatinib. Case report and literature review. Journal of Modern Oncology. 2021;23(1):156–161. (In Russ.) https://doi.org/10.26442/18151434.2021.1.200785.

13. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.

14. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. https://doi.org/10.1016/j.jhep.2021.11.030.

15. Kim Y, Kim JS, Kang B, Kim I, Kim H, Lee WS et al. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year. Cancer Res Treat. 2024;56(4):1231–1239. https://doi.org/10.4143/crt.2024.237.

16. Zheng Z, Zhou L, Gao S, Yang Z, Yao J, Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and metaanalysis. Int J Med Sci. 2013;10:65364. https://doi.org/10.7150/ijms.6050.

17. Cheon J, Yoo C, Hong JY, Kim HS, Lee DW, Lee MA et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int. 2022;42:674–681. https://doi.org/10.1111/liv.15102.

18. Li DZ, Guo J, Song QK, Hu XJ, Bao XL, Lu J. Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis. Transl Cancer Res. 2022;11:4037–4050. https://doi.org/10.21037/tcr-22-1197.

19. Zhang D, Liu Z, Yin X, Qi X, Lu B, Liu Y et al. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: a systematic review and meta-analysis. Int J Biol Markers. 2018;33:266–274. https://doi.org/10.1177/1724600818760234.

20. Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides. J Hepatocell Carcinoma. 2021;8:1089–1115. https://doi.org/10.2147/JHC.S318070.